| dbo:abstract
|
- Volanesorsen, sold under the brand name Waylivra, is a triglyceride-reducing drug. It is a second-generation 2'-O-methoxyethyl (2'-MOE) chimeric antisense therapeutic oligonucleotide (ASO) that targets the messenger RNA for apolipoprotein C3 (apo-CIII). The most common side effects include reduced platelet levels and reactions at the site of the injection such as pain, swelling, itching, or bruising. Volanesorsen, is an 'antisense oligonucleotide,' a very short piece of synthetic RNA (a type of genetic material). It has been designed to block the production of a protein that slows down the breakdown of fats called apolipoprotein C-III. By blocking the production of this protein, the medicine reduces the level of triglycerides in the blood and, as a result, fat accumulation in the body, which is expected to reduce the risk of pancreatitis. (en)
|
| dbo:alternativeName
| |
| dbo:casNumber
| |
| dbo:chEMBL
| |
| dbo:drugbank
| |
| dbo:fdaUniiCode
| |
| dbo:kegg
| |
| dbo:pubchem
| |
| dbo:thumbnail
| |
| dbo:wikiPageExternalLink
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 14128 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:atcPrefix
| |
| dbp:atcSuffix
| |
| dbp:c
| |
| dbp:casNumber
| |
| dbp:chembl
| |
| dbp:chemspiderid
| |
| dbp:drugbank
| |
| dbp:h
| |
| dbp:iupacName
|
- all-P-ambo-2'-O--P-thioadenylyl--2'-O--P-thioguanylyl--2'-O--5-methyl-P-thiocytidylyl--2'-O--5-methyl-P-thiouridylyl--2'-O--5-methyl-P-thiouridylyl--2'-deoxy-5-methyl-P-thiocytidylyl--P-thiothymidylyl--P- thiothymidylyl--2'-deoxy-P-thioguanylyl--P-thiothymidylyl--2'-deoxy-5-methyl-P-thiocytidylyl--2'-deoxy-5-methyl-P-thiocytidylyl--2'-deoxy-P-thioadenylyl--2'-deoxy-P-thioguanylyl--2'-deoxy-5-methyl-P-thiocytidylyl--2'-O--5-methyl-P-thiouridylyl--2'-O--5-methyl-P-thiouridylyl--2'-O--5-methyl-P-thiouridylyl--2'-O--P-thioadenylyl--2'-O--5-methyluridine (en)
|
| dbp:jmol
| |
| dbp:kegg
| |
| dbp:legalEu
| |
| dbp:legalStatus
| |
| dbp:legalUk
| |
| dbp:n
| |
| dbp:o
| |
| dbp:p
| |
| dbp:pubchem
| |
| dbp:routesOfAdministration
| |
| dbp:s
| |
| dbp:smiles
|
- Cc1cn[C@H]2C[C@@H]OPS (en)
|
| dbp:stdinchi
| |
| dbp:stdinchikey
|
- IJUQCWMZCMFFJP-GQSLRNSLSA-N (en)
|
| dbp:synonyms
|
- ISIS 304801, ISIS-APOCIIIRx (en)
|
| dbp:tradename
| |
| dbp:unii
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| rdf:type
| |
| rdfs:comment
|
- Volanesorsen, sold under the brand name Waylivra, is a triglyceride-reducing drug. It is a second-generation 2'-O-methoxyethyl (2'-MOE) chimeric antisense therapeutic oligonucleotide (ASO) that targets the messenger RNA for apolipoprotein C3 (apo-CIII). The most common side effects include reduced platelet levels and reactions at the site of the injection such as pain, swelling, itching, or bruising. (en)
|
| rdfs:label
| |
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:product
of | |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is dbp:products
of | |
| is foaf:primaryTopic
of | |
